The magnitude of the PFS improvement (17.7 vs 2 months) is unusually large for an interim analysis in mCRPC, but the small sample and single-arm comparison warrant caution. Watch for full dataset at trial completion (target Q4 2027) and any partnership or licensing interest from larger pharma. The protocol modification to earlier-line therapy expands the addressable patient population.
Price Chart
Executive Summary
Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer, showing a statistically significant improvement in median progression-free survival (17.7 months combination vs 2 months apalutamide alone, P=0.0008). The company modified the protocol to enroll patients earlier in disease progression and targets trial completion by Q4 2027. This is a clinical-stage biotech with no revenue — the data is promising but early, and the stock remains highly speculative.
Key Facts
- Interim Phase 2 data showed median PFS of 17.7 months for ENV-105 + apalutamide vs 2 months for apalutamide alone (P=0.0008)
- Protocol modified to enroll patients earlier — after PSA increase on upfront androgen signaling inhibitor, not after 1-2 prior anti-androgen agents
- Modified protocol randomizes patients to enzalutamide alone or enzalutamide + ENV-105
- Company targets Phase 2 trial completion in or before Q4 2027
- ENV-105 is a first-in-class CD105 antibody targeting drug resistance mechanisms
Financial Impact
No financial data in filing; clinical-stage company with no revenue. Positive interim data could materially increase probability of success and partnership/licensing value.
Risk Factors
- Interim data from small Phase 2 trial may not replicate in larger or more rigorous studies
- Protocol modification changes comparator from apalutamide to enzalutamide, complicating cross-trial comparisons
- Clinical-stage biotech with no approved products or revenue — high cash burn risk
- Trial completion not expected until Q4 2027 at earliest
- No mention of safety data or response rate in this interim release
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045844 |
| Exhibit: ex99-1.htm | 0001493152-26-045844 |
| Document: 0001493152-26-045844-index-headers.html | 0001493152-26-045844 |
| Document: 0001493152-26-045844-index.html | 0001493152-26-045844 |
| Document: 0001493152-26-045844.txt | 0001493152-26-045844 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.15 $0.8287 | ▼ −27.94% | ▼ −27.80% | $0.5360 (−53.39%) |
Jul 22, 2026 13w ago | 8-K | $0.3127 $0.2990 | ▼ −4.38% | ▼ −1.98% | $0.5360 (+71.41%) |
Jul 15, 2026 14w ago | 8-K | $0.3180 $0.3127 | ▼ −1.67% | ▼ −0.69% | $0.5360 (+68.55%) |
Jun 4, 2026 20w ago | 8-K | $0.4660 $0.4580 | ▼ −1.72% | ▲ +0.84% | $0.5360 (+15.02%) |
May 26, 2026 21w ago | DEFA14A | $0.5170 $0.4620 | ▼ −10.64% | ▼ −11.11% | $0.5360 (+3.68%) |
Feb 26, 2026 34w ago | 8-K | $0.5520 $0.6560 | ▲ +18.84% | ▲ +19.97% | $0.5360 (−2.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers